Noble Financial Issues Optimistic Estimate for CRDF Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Research analysts at Noble Financial raised their Q1 2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a note issued to investors on Thursday, March 26th. Noble Financial analyst R. Leboyer now anticipates that the company will earn ($0.14) per share for the quarter, up from their previous forecast of ($0.19). Noble Financial has a “Outperform” rating and a $12.00 price objective on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. Noble Financial also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.64) EPS.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.07. The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.13 million. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%.

CRDF has been the subject of several other research reports. Wall Street Zen raised Cardiff Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Piper Sandler lowered their price target on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Cardiff Oncology in a report on Wednesday, January 28th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.10.

Cardiff Oncology Stock Performance

CRDF stock opened at $1.55 on Monday. Cardiff Oncology has a one year low of $1.48 and a one year high of $4.56. The firm has a market cap of $105.96 million, a PE ratio of -2.25 and a beta of 1.32. The firm’s 50 day moving average price is $1.89 and its 200-day moving average price is $2.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Laurion Capital Management LP grew its stake in shares of Cardiff Oncology by 7.3% in the fourth quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after buying an additional 180,866 shares in the last quarter. Acorn Capital Advisors LLC grew its position in Cardiff Oncology by 39.3% in the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after acquiring an additional 553,317 shares in the last quarter. Geode Capital Management LLC grew its position in Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after acquiring an additional 104,409 shares in the last quarter. Franklin Resources Inc. purchased a new stake in Cardiff Oncology during the fourth quarter worth about $3,388,000. Finally, State Street Corp increased its stake in Cardiff Oncology by 4.0% during the fourth quarter. State Street Corp now owns 1,191,647 shares of the company’s stock worth $3,349,000 after purchasing an additional 45,288 shares during the period. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.